The detection of KRAS and NRAS mutation in CRC is mostly performed on archived surgical tumor tissue samples or tumor biopsy samples using traditional point mutation detection methods (e.g. quantitative polymerase chain reaction, quantitative PCR and amplification refractory mutation system, ARMS) or sequencing technique (e.g. Sanger sequencing) [12–14]. This evidence concerns the gene KRAS and neoplasm.